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Cancer Associated Fibroblasts: The Architects of Stroma
Remodeling
Alice Santi, Fernanda G. Kugeratski, and Sara Zanivan*
Fibroblasts have exceptional phenotypic plasticity and capability to secrete
vast amount of soluble factors, extracellular matrix components and
extracellular vesicles. While in physiological conditions this makes fibroblasts
master regulators of tissue homeostasis and healing of injured tissues, in
solid tumors cancer associated fibroblasts (CAFs) co-evolve with the disease,
and alter the biochemical and physical structure of the tumor
microenvironment, as well as the behavior of the surrounding stromal and
cancer cells. Thus CAFs are fundamental regulators of tumor progression and
influence response to therapeutic treatments. Increasing efforts are devoted
to better understand the biology of CAFs to bring insights to develop
complementary strategies to target this cell type in cancer. Here we highlight
components of the tumor microenvironment that play key roles in cancer
progression and invasion, and provide an extensive overview of past and
emerging understanding of CAF biology as well as the contribution that
MS-based proteomics has made to this field.
1. The Tumor Microenvironment
Neoplastic lesions in situ are confined within a layer of base-
ment membrane which physically separates epithelial cells from
the underlying stromal compartment. During malignant trans-
formation, cancer cells acquire invasive properties, breach the
basement membrane, and invade the surrounding stroma (re-
ferred to also as tumor microenvironment) (Figure 1). In tumors
in situ, cancer and stromal cells can communicate through the
basement membrane; in invasive tumors, cancer and stromal
cells are in direct contact and establish a complex crosstalk that
evolves alongside tumor development and leads to alterations of
the microenvironment[1,2] In healthy tissue the stroma is popu-
lated by few resident fibroblasts embedded within a vascularised
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physiological extracellular matrix (ECM).
In tumors, the stroma contains in-
creased number of fibroblasts, which
are pathologically activated and called
cancer associated fibroblasts (CAFs),
blood/lymphatic vessels, which are often
dysfunctional, immune cell infiltrates,
and an ECM profoundly remodeled
compared with the physiological one.
CAFs are a heterogeneous and highly
secretory population of cells which play
key roles in constructing a microenvi-
ronment that modulates functions and
behavior of the surrounding cells during
tumor progression. For this reason CAFs
have been referred to as the “architects of
cancer pathogenesis”[3] and are emerging
as a promising therapeutic target.
We will briefly describe three major
components of the tumor stroma—
blood/lymphatic vessels, immune
system, and ECM—and provide a detailed overview of CAFs and
how they regulate those stromal compartments.
1.1. The Tumor Vasculature
The tumor vasculature has fundamental roles in cancer because
it fuels the uncontrolled growth of cancer cells by refurbishing
the tumor with nutrients and oxygen and removing waste prod-
ucts. Furthermore, it provides a route for the cancer cells to es-
cape the primary tumor to form distant metastases.[4,5] Endothe-
lial cells (ECs) are the key players in the formation and functional
regulation of vessels. ECs line the blood vessel wall and are in
direct contact with the blood, pericytes, or smooth muscle cells
which wrap around the ECs, and macrophages which help the
remodeling of the vasculature.[2,6,7]
Tumor vessels originate via different processes, including
growth from preexisting vessels that infiltrate the tumor (angio-
genesis), de novo formation from EC precursors recruited within
the tumor (vasculogenesis), or hijacking of the existent vascu-
lature by the cancer cells (co-option).[8–11] Tumor vasculariza-
tion is driven by numerous factors, including vascular endothe-
lial growth factor A (VEGFA), stromal cell-derived factor 1 (also
known asC-X-Cmotif chemokine 12, CXCL12), fibroblast growth
factors (FGFs), platelet-derived growth factor alpha (PDGFα),
transforming growth factor beta (TGF-β), angiopoietin 2 (ANG-
2), interleukin 8 (IL-8), IL-6, matrix metalloproteinase-2 (MMP2),
MMP9 (reviewed in [12–14]). Due to the excessive secretion of
those factors by cancer and stromal cells, the organization and
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Figure 1. Tumor progression. Schematic representation of tumor development with highlighted stromal components that contribute to progression and
invasion.
structure of the tumor vasculature is often abnormal. Vessels
have irregular branches and are tortuous. Moreover, they are
structurally unstable due to defective coverage with pericytes and
basement membrane, and unstable EC–EC and EC–pericyte in-
tercellular junctions.[15–19] Tumor dysplasia and the rapid growth
of the tumormass can create high density regions where new ves-
sels cannot penetrate and the resident ones are compressed.[20]
These abnormalities lead to the establishment of a tumor vascu-
lature that is leaky. This aids cancer cell intravasation to form dis-
tant metastases,[21] impairs immune cell infiltration,[22] and cre-
ates hypoxic and necrotic tumor regions.[23] Dysfunctional vessels
also hamper the transport and efficacy of chemo and radiation
therapies.[12]
Also lymphatic vessels provide a route for metastatic spread.
In physiological conditions, the lymphatic vasculature controls
fluid homeostasis, lipid absorption, and immune surveillance.
In tumors, lymphatic vessels undergo a structural remodeling
through lymphangiogenesis and enlargement of the surface area.
These changes enhance lymphatic EC–cancer cell contact and fa-
cilitate the access of cancer cells into the lymphatic system to es-
tablish lymph node metastases.[24–27] The main drivers of lym-
phangiogenesis are VEGFC and VEGFD, which can be secreted
by cancer cells, CAFs, and immune cells.[28–30]
1.2. The Immune System
Intratumoral immune infiltrates are composed of various cell
types of the innate (macrophages, dendritic cells, mast cells,
granulocytes, natural killer cells) and adaptive immune system
(B cells and CD4+ and CD8+ T lymphocytes, natural killer T cells,
and γ δ T cells), and their composition is determined by tumor-
derived signals, such as the expression of cytokines, and the ex-
pression of genes specific of the normal tissue of origin.[31,32]
As an example, there are similar numbers of macrophages
in the stroma of human lung adenocarcinoma and normal
lung, but only macrophages within the tumor lesion have an
immunosuppressive and pro-tumorigenic phenotype.[33] The
main role of immune infiltrates is to recognize and eliminate
cancer cells. However, their tumor blocking functions can be sup-
pressed by cytokines and growth factors secreted by intratumoral
myeloid, cancer, and stromal cells. A key example is the tumor-
induced expression and activation of receptors on T cells, such
as programmed cell death protein-1 (PD1), T-cell immunoglob-
ulin mucin 3 (Tim-3), and cytotoxic T-lymphocyte protein 4
(CTLA4), which inhibit their antitumorigenic functions.[34,35] An-
other mechanism that inhibits immune infiltrate involves ECs.
Tumor ECs upregulate adhesion molecules, such as stabilin-1
(STAB1, also known as CLEVER1) mucosal vascular addressin
cell adhesion molecule 1 (MADCAM1), and activated leukocyte
cell adhesion molecule (CD166), that selectively promote the in-
filtration of regulatory T cells, which secrete immunosuppressive
cytokines.[36,37]
1.3. The Extracellular Matrix
The ECM is a complex network of macromolecules whose struc-
ture and composition define its biochemical and biomechanical
properties. Collagens, laminins, glycoproteins such as tenascin
C (TNC) and fibronectin, proteoglycans, and polysaccharides are
major ECM components.[38,39] The ECM provides structural sup-
port to the cells and transduces biomechanical signals that mod-
ulate cellular functions, including motility, proliferation, and
differentiation. Moreover, it binds to growth, survival, motility,
and angiogenic factors such as TGF-β, FGF, PDGF, epidermal
growth factor (EGF), hepatocyte growth factor (HGF), and VEGF,
thus being a reservoir of factors whose availability depends on
ECM remodeling.[40,41]
Tumor progression is often accompanied by a desmoplas-
tic reaction, such that the ECM can constitute the majority
of the tumor mass. Both cancer and stromal cells contribute
to deposition of ECM, and its properties alter tumor features,
such as the potential to form metastasis.[42] Cells modify the
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ECM not only by secreting ECM components, but also by se-
creting enzymes which modify the ECM, such as transglu-
taminases (TGMs) and lysyl oxidases (LOXs), which crosslink
ECM components.[43,44] Conversely, MMPs, a disintegrin and
metalloproteinases (ADAMs), and a disintegrin and metallo-
proteinase with thrombospondin motifs (ADAMTSs) proteins
proteolytically degrade ECM components and release ECM-
bound soluble factors.[45–47] The activity of these proteases is
inhibited by tissue inhibitors of metalloproteinases.[48] The dys-
regulated activity of these enzymes, together with the exces-
sive deposition of ECM components and their reduced turnover,
are typical in malignant lesions. Thus tumor ECM is different
from physiological ECM and directly influences tumor progres-
sion (reviewed in [49,50]). For example, the tumor ECM is usually
stiffer than physiological ECM, and this plays key roles in main-
taining CAF phenotype, enhancing cancer and stromal cell in-
vasion, cancer cell-endothelium interactions, epithelial to mes-
enchymal transition (EMT) transformation, and immune cell
recruitment.[38,51–54]
1.4. CAFs
1.4.1. The Origins of CAFs
In physiological conditions, fibroblasts are low proliferative
spindle-shaped cells located in the connective tissue of most
organs. Fibroblasts secrete ECM components and ECM-
remodeling enzymes to maintain the homeostasis of the stroma
and define the structural integrity and mechanical properties
of organs. Fibroblasts also control the polarity and function
of the epithelium by producing basement membrane.[55,56] In
1971, Giulio Gabbiani described for the first time the existence
of fibroblastic cells with contractile properties, namely my-
ofibroblasts, in the granulation tissue, and hypothesized that
myofibroblasts had reparative activity during wound healing.[57]
Later studies revealed that the contractility was primarily me-
diated by the expression of ED-A,[58] a splice variant of cellular
fibronectin, and the actin isoform alpha-smooth muscle actin
(α-SMA). The mechanical stress generated after a wound and
the inflammatory factors released by injured tissues induce
expression of ED-A and TGF-β1 in normal resident fibroblasts.
TGF-β1, in turn, induces the expression of α-SMA, which is
incorporated in the stress fibers. α-SMA was initially described
in smooth muscle cells, but is now a widely used marker of
myofibroblasts andmyofibroblast-like cells.[59] In 1979, cells with
morphological and molecular properties of myofibroblasts were
described in the stroma of solid tumors.[60] Thesemyofibroblastic
cells are referred to as CAFs.
CAFs originate from the activation of resident fibroblasts[61]
or other precursor cells. CAFs can derive from bone marrow-
derived mesenchymal stem cells,[62] epithelial cells,[63,64] car-
cinoma cells,[63] ECs,[65] pericytes,[66] smooth muscle cells,[63]
adipocytes,[67] fibrocytes,[68] or from some specialized cells such
as stellate cells in pancreas and liver,[69] myoepithelial cells in
breast,[70] and pericryptal myofibroblasts in the gastrointestinal
tract.[71] This spectrum of precursors explains, at least in part, the
heterogeneity of CAFs. CAF activation is triggered by a variety of
stimuli, including cancer cell-derived TGF-β1, PDGFα, PDGFβ,
basic FGF (bFGF, also known as FGF2), and IL-6,[72–76] and envi-
ronmental stimuli, such as hypoxia, oxidative stress, and matrix
stiffness.[52,77,78] All these stimuli may cooperate to determine dif-
ferent CAF phenotypes further contributing to their heterogene-
ity. As a consequence, while α-SMA represents the oldest and
commonly used marker to assess CAF phenotype, not all CAFs
express α-SMA. Prolyl endopeptidase FAP (also known as fibrob-
last activation protein), fibroblast-specific protein 1 (FSP1, also
known as S100A4), and the mesenchymal cell marker vimentin
are expressed at higher levels in CAFs compared to non-activated
fibroblasts and are also considered CAF markers. Conversely,
the cell surface protein CD36 and caveolin 1 (CAV1) levels de-
crease upon activation (CAF markers reviewed in [13,79]). None of
these markers are exclusively expressed in CAFs, and the major-
ity are not synchronously expressed. For example, a distinct CAF
subpopulation FSP1+, α-SMA−, PDGFRβ−, and NG2− has been
identified within the stroma of tumors isolated from Rip1Tag2
model of β-cell carcinogenesis and murine orthotopic 4T1 breast
tumors.[80] A CAF subpopulation α-SMAhigh, which localizes ad-
jacent to the cancer cells, and one α-SMAlow and IL-6high, which
secretes inflammatory factors and is located distant from the can-
cer cells, have been characterized in murine model of pancreatic
adenocarcinoma (PDAC).[81] Several combinations of α-SMA+,
S100A4+, and FAP+ CAF subpopulations have been identified
in MMTV-PyMT breast tumors isolated at different stages of the
progression, and in human cervical, head and neck and vulval
squamous cell carcinoma (SCC) CAF lines.[52] In tissue sections
of esophageal carcinoma, colorectal adenocarcinoma, and head
and neck SCC, a subset of α-SMA+ CAFs was found associated
with regions with elongated collagen fibers.[82] While CAF hetero-
geneity starts to become well documented, future studies need
to address the extent of this heterogeneity during tumor progres-
sion, in different tumor types, and whether distinct functions are
associated to each CAF phenotype.
Upon activation, CAFs secrete a vast repertoire of growth
factors, such as HGF, EGF, connective tissue growth factor
(CTGF) and insulin-like growth factor (IGF), cytokines, including
CXCL12 and IL-6, extracellular vesicles (EVs), metabolites, ECM
components, particularly collagens, fibronectin and TNC, and
ECM-remodeling enzymes, such asMMPs, LOXs, and TGMs. All
these factors directly affect the behavior of the surrounding cells
and remodel the ECM (see below and Figure 2). Thus CAFs aid
tumor development, from the early stages of tumorigenesis un-
til cancer cells colonize distant organs to form metastasis.[3,13,63]
CAFs also contribute to resistance to therapy.[83,84]
1.4.2. CAFs Promote Cancer Cell Migration and Invasion
CAFs modulate migratory and invasive traits of cancer cells indi-
rectly by remodeling the ECM and directly by influencing cancer
cell phenotype and aiding cancer cell migration.
In organotypic co-cultures of head and neck SCC CAFs with
SCC12 cancer cells, CAFs deposit ECM tracks that lead the col-
lective invasion of cancer cells in a mechanism dependent on
protease- and force-mediated ECM remodeling. Blocking α3 and
α5 integrin or Rho associated protein kinase (ROCK) in CAFs
decreased their ability to produce ECM tracks to facilitate can-
cer cell migration.[85] Accordingly, in patient- and PyMT-derived
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Figure 2. CAF functions. Schematic representation of key CAF functions and CAF-derived factors involved.
mammary CAFs, ROCK was required for the expression of cy-
toskeletal regulators and stiffening of the ECM via nuclear local-
ization of the transcriptional coactivator YAP (YAP1). Silencing
YAP1 in PyMT CAFs reduced their ability to contract 3D colla-
gen gels and to assemble stiff ECM, and this reduced the in-
vasiveness of SCC12 cancer cells in organotypic co-cultures.[52]
In CAFs, ROCK-dependent actomyosin contractility was also in-
duced through GP130-IL6ST/JAK1 signaling activated by onco-
statinM and blocking JAK1 signaling in CAFs reduced their capa-
bility to contract gel and induce SCC12 invasion.[86] Highlighting
the importance of ROCK signaling in CAFs and its potential as
target for therapies, in murine models of PDAC targeting ROCK
with small molecules reduced fibroblast/stellate cell activation,
ECM deposition and this, in turn, enhanced gemcitabine uptake
and improved survival.[87,88]
Also micro RNAs control CAF contractility. The miR-200s
negatively regulate the ability of human mammary CAFs to con-
tract collagen gels and promote cancer cell invasion. MiR-200s-
silenced normal fibroblasts acquired features of CAFs, such as in-
creased levels of α-SMA and accelerated migration and invasion,
in vitro. Conversely, ectopic expression of miR-200s in CAFs re-
duced α-SMA levels, cell invasion, and the ability to contract col-
lagen gels. Subcutaneously cotransplanted CAFs overexpressing
miR-200s with MDA-MB-231 breast cancer cells formed smaller
and less invasive tumors compared with those formed with con-
trol CAFs.[89]
The ability of CAFs to remodel the ECM is controlled also by
intratumoral hypoxia,[90] a typical hallmark of solid tumors. Hy-
poxia induces secretion of prolyl 4-hydroxylase subunit alpha-1
and alpha-2 (P4HA1, P4HA2), which are required for collagen
deposition, and procollagen-lysine,2-oxoglutarate 5-dioxygenase
2 (PLOD2), which is essential for the alignment of the ECM
fibers. Thus, the ECM deposited by hypoxic fibroblasts promoted
changes in morphology, adhesion, and migration of breast can-
cer cells and enhanced invasion.[91] Moreover fibroblasts express-
ing activated hypoxia-inducible factor 1 alpha (HIF1α) were pro-
tumorigenic and pro-metastatic when cotransplanted in MDA-
MB-231 xenografts.[92] Conversely, hypoxia decreased expression
of α-SMA and impaired contractile forces and the ability to re-
model the ECM in vulval and head and neck SCC CAFs cul-
tured in 3D collagen gels. In vivo, genetic or pharmacological
ablation of prolyl hydroxylase 2 (EGLN1 also known as PHD2),
which stabilizes the transcription factor HIF1α, in CAFs cotrans-
planted orthotopically with 4T1 breast cancer cells decreased
tumor stiffness, invasion and liver metastasis.[93] Accordingly,
HIF1α-depletion,[94] but not depletion of PHD2,[95] in fibroblasts
before tumor onset accelerates tumorigenesis in a MMTV-PyMT
model. It is clear that howhypoxia influences CAF phenotype and
their pro-invasive functions is still controversial. Future studies
are required to address whether hypoxia has distinct effects on
different CAF subpopulations or whether the effect depends on
tumor type or other tumor or stromal factors.
Cancer cells that undergo EMT have enhanced migratory and
invasive traits while losing adhesive properties. CAFs play a role
in this process by promoting EMT. Patient-derived CAFs iso-
lated from prostate tumors triggered EMT and invasiveness of
PC3 prostate cancer cells through ametalloproteinase-dependent
mechanism. As a result CAFs cotransplanted with PC3 cancer
cells showed enhanced metastasis.[73] The conditioned medium
(CM) of cultured mammary CAFs was able to induce EMT and
invasive behavior of MCF7 breast cancer cells and MCF10A
breast epithelial cells.[96] In line with this report, treatment of
MCF7, T47D, and MDA-MB-231 cells with CM from patient-
derived mammary CAFs promoted the expression of EMT
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markers through TGF-β signaling activation.[97] CAFs isolated
from non-small cell lung cancer (NSCLC) tissue expressed more
IL-6 compared to normal lung fibroblasts, and their CM in-
duced an IL-6-dependent EMT in NSCLC cells and resistance to
cisplatin treatment. Moreover, IHC analysis of NSCLC tissues
showed that stromal IL-6 levels correlate with EMT phenotype
of cancer cells.[98] CAFs isolated from human gastric carcinoma
tissue secrete Galectin 1 (LGALS1), which binds to β1 inte-
grin in MGC-803 gastric cancer cells thus inducing EMT via
upregulation of the glioma-associated oncogene 1 (GLI1).[99] Fi-
nally, CAFs can support invasion by establishing physical in-
teractions with the cancer cells. Human lung adenocarcinoma
and vulval SSC CAFs promoted A431 SCC cancer cell migration
and invasion by establishing heterophilic N-cadherin/E-cadherin
interactions.[100] Moreover, CAFs can co-travel in the blood with
circulatingmurinemetastatic lung carcinoma cancer cells to sup-
port cancer cell viability and provide them with a growth ad-
vantage at the metastatic site.[101] A better understanding of the
signaling downstream of such heterotypic cell–cell interactions
could provide insights to develop strategies to target invasion and
metastasis.
1.4.3. CAFs Restrain Tumor Progression
CAFs are mostly described as pro-tumorigenic. However, CAFs
can also restrain tumorigenesis. Depletion of α-SMA+ prolifer-
ating cells either at non-invasive pancreatic intraepithelial neo-
plasia or PDAC stage in KRasG12D model accelerated the pro-
gression of the disease.[102] Similarly, deletion of the desmoplas-
tic driver Sonic hedgehog (Shh) in the cancer cells of a PDAC
model promoted aggressiveness.[103] Patient-derived mammary
fibroblasts, 199Ct CAF line, and WI38 and HS68 fibroblast lines
were found to secrete high levels of slit homolog 2 protein
(SLIT2). CAF-derived SLIT2 suppresses invasion of breast can-
cer cells expressing its receptor roundabout homolog 1 (ROBO1),
through inhibition of PI3K and β-catenin signaling. Consistently,
tumor growth was suppressed in ROBO1 expressing HCC1937
xenografts, while enhanced in ROBO1-depleted MDA-MB-231
xenografts cotransplanted with SLIT2 expressing 199Ct fibrob-
lasts. Finally, in breast cancer patients, high SLIT2 levels in the
stroma and high ROBO1 levels in the cancer cells were indica-
tive of better clinical outcome.[104] Triple negative breast cancer
(TNBC) cells suppressed the expression of the secreted protein
asporin in stromal fibroblasts. Notably, CAF-derived asporin in-
hibits TGF-β signaling and EMT in breast cancer cells, and over-
expression of asporin in patient-derived normal mammary fi-
broblasts cotransplanted with MDA-MB-468 xenograft reduced
tumor growth and metastasis.[105]
The conundrum that CAFs can either promote or restrain tu-
mors needs further attention in the future. More effort should be
devoted to identify the molecular mechanisms behind these op-
posite functions to provide insights for the development of ther-
apies that specifically target pro-invasive CAF functions, while
promoting those that restrain tumors.
1.4.4. CAFs Control Vascular and Immune Systems
Early evidence that CAFs induce tumor vascularization came
from transgenic mice expressing GFP under the VEGF promoter
and transplanted with mammary carcinoma MCaIV or hepato-
cellular carcinoma HCaI cells, or crossed with PyMT mice. In
these models cancer cells induced VEGF expression in intra-
or peri-tumoral fibroblasts and these VEGF-expressing regions
were vascularized.[106] The role of CAFs in tumor vascularization
has been confirmed in other models. In an HPV cervical carcino-
genesis model, PDGFRs-expressing CAFs induced cancer cell
proliferation and angiogenesis. The pro-angiogenic effect was
due to FGF2 secretion, which was induced by cancer cell-derived
PDGF, and this was abrogated by pharmacological treatment to
block stromal PDGFR signaling.[107] After co-transplantation of
patient-derived mammary CAFs and MCF7 breast carcinoma
cells expressing activated HRas oncogene (MCF7-HRas), CAFs
induced the formation of tumors extensively vascularized com-
pared with those grown with normal fibroblasts. In this model,
CAFs secreted high levels of CXCL12 which induced endothelial
progenitor cell recruitment.[108] Moreover, PyMT CAFs embed-
ded in matrigel plugs subcutaneously transplanted induced
vascularization of the plug, and silencing of YAP1 decreased this
pro-angiogenic capacity.[52] Stromal deletion of the tumor
suppressor Pten promoted angiogenesis and tumorigenesis in
MMTV-ErbB2/neu and MMTV-PyMT breast cancer models. In
MMTV-ErbB2/neu tumors, stromal Pten depletion before tumor
onset induces Ets2-dependent expression of ECM remodeling,
wound healing, and chronic inflammation factors in CAFs,
as well as intratumoral recruitment of macrophages. Stromal
Ets2 depletion in stromal Pten-null mice reduces growth, vas-
cularization, and macrophage recruitment in tumors grown
from orthotopically transplanted NT2.5 ErbB2-expressing cancer
cells.[109] The pool of CAF-secreted cytokines also contributes
to recruit and modulate polarization and functions of immune
cells. The expression of pro-inflammatory factors, such as
cyclooxygenase 2 (COX2), CXCL1, CXCL2, the protein CYR61
(CYR61/CCN1), IL-1β, IL-6, and osteopontin, is mediated by
NF-kB in dysplasia-derived CAFs from a murine model of HPV
skin carcinogenesis; CAFs required NF-kB to promote tumor
growth, macrophage recruitment, and vascularization when or-
thotopically cotransplanted with murine PDSC5 skin carcinoma
cells.[110] IL-6 secreted by normal skin fibroblasts co-cultured
in physical contact with monocytes promoted monocyte differ-
entiation into macrophages.[111] Accordingly, in an orthotopic
4T1 model, FAP+ CAF-deleted tumors had reduced levels of
IL-6 and IL-4 while increased IL-2 and IL-7, and this enhanced
the recruitment of antitumor immune cells (DCs and CD8+ T
cells), while inhibiting the recruitment of pro-tumorigenic ones
(F4/80+ tumor associated macrophages, TAMs, CD11b+/Gr-1+,
myeloid derived suppressor cells, MDSCs, and CD4+/FOXP3+
T regulatory cells, Tregs). As a consequence, FAP+ CAF deple-
tion inhibited the formation of lung metastasis and enhanced
the anti-metastatic effects of chemotherapy (doxorubicin).[112]
In the KPC murine model of PDAC, FAP+ CAFs had pro-
inflammatory and desmoplastic signatures and suppressed
cancer immune surveillance. Partial toxin-induced depletion of
FAP+ CAFs, as well as pharmacological blockage of CXCL12
signaling by inhibiting its receptor C-X-C chemokine recep-
tor 4 (CXCR4), reduced tumor growth and enhanced T cell
accumulation within the tumor, thus sensitizing tumors to
α-PDL1 treatment. This effect was possibly due to the capa-
bility of CXCL12 to block infiltration of CXCR4-expressing
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T cells.[113] MRC5 fibroblasts, foreskin fibroblasts, and
mammary CAFs co-cultured with MDA-MB-231, Hs578T, MDA-
MB-436, MDA-MB-157, or HCC1937 basal-like ER− breast can-
cer cells induced interferon-stimulated genes, which drovemech-
anisms of resistance to chemotherapy and radiation through the
activation of STAT1 in the cancer cells. STAT1 activation
was induced through the pattern recognition receptor RIG-I,
which was activated by binding to RNA, 7SL, Cytoplasmic 1
(RN7SL1). RN7SL1 was transferred to the cancer cells through
fibroblast-derived EVs. Activation of RIG-I in the cancer cells
led to NOTCH/MYC pathway activation in fibroblasts which,
in turn, enhanced stromal RN7SL1 availability, thus establish-
ing a positive feed-back loop. RN7SL1-containing EVs from
MYC-activated mouse embryonic fibroblasts inoculated into
mice were able to activate circulating myeloid and dendritic
cells, suggesting that fibroblast-derived RNAs can control tumor
progression by horizontal transfer to cancer cells and also
circulating inflammatory cells.[114,115]
2. CAFs and MS-Proteomics
Modern MS-based proteomics allows the measurement of cell
proteome and secretome, such as CM and ECM from cell cul-
tures and ECM from tissue samples, at global scale. Fibroblasts
are highly secretory cells, thus MS-proteomics provides unique
opportunities to understand CAF biology and their ability to alter
the tumor microenvironment.
2.1. CAF Signatures Unraveled by Total Proteome Analysis
Several proteomic studies have assessed differences between
CAFs and their normal fibroblast counterpart to identify potential
markers and regulators of CAF functions.
Comparative proteomic analysis of murine CAFs isolated
from sporadic colon cancer with their matched normal fi-
broblasts revealed upregulation of latent transforming growth
factor beta binding protein 2 (LTBP2), farnesyl diphosphate
synthase (FDPS), and cadherin 11 (CDH11) in CAFs. LTBP2
and CDH11 expression were both induced by TGF-β and el-
evated in the stroma of colon cancer tissues.[116] α-SMA+ and
vimentin+ cultured fibroblasts derived from 11 pairs of hu-
man gastric cancer and tumor-adjacent tissues expressed dif-
ferent levels of proteins related to actin filaments, and this
mirrored higher migration and proliferation rates of CAFs.[117]
Similarly, the cellular proteome of α-SMA+ CAFs derived
from two human invasive mammary ductal carcinoma and
SMA− normal fibroblasts from matched non-malignant ad-
jacent region were different. Notably, tumor-adjacent fibrob-
lasts had an intermediate proteomic profile between normal fi-
broblasts and CAFs.[118] Proteome and secretome analysis of
immortalized fibroblasts isolated from normal breast andMCF7-
HRas cell-activated CAFs[119] defined that CAFs had a myofibrob-
lastic phenotype. Moreover, it unraveled altered levels of pro-
teins related to metabolism, cell morphogenesis, differentiation,
adhesion, and motility. Consistent with this molecular portrait,
CAFs induced invasive behavior of A2780, MCF10DCIS.com,
and MDA-MB-231 cancer cells and human umbilical vein en-
dothelial cells.[120]
Some studies, instead, compared the whole proteome of
patient tumor tissues and neighboring regions. To discrimi-
nate between cancer cell and stromal contribution to the pro-
teomic data, cell-type specific proteome profiles were used as
reference. For breast cancer, human ZR-75-1 cancer cells and
TGF-β-stimulated or IL-1β-stimulated human fibroblasts to
mimic myofibroblast-like or inflammation-induced CAFs, re-
spectively, were used. Fibroblast-derived proteins were hardly
detected in biopsies from central tumor regions, while they
were in those from the surrounding tissue. Most of the iden-
tified proteins, including fibulin-5 (FBLN5), solute carrier fam-
ily 2 facilitated glucose transporter member 1 (SLC2A1) and cell
surface glycoprotein MUC18, were more abundant in TGF-β-
induced fibroblasts, indicating the presence ofmyofibroblast-like
CAFs in peripheral tumor regions.[121] For hepatocellular carci-
nomas, reference profiles were generated from cultured patient-
derived cancer cells and CAFs. Higher levels of PLOD2, eukary-
otic translation initiation factor 3 subunit H (EIF3H), ubiqui-
tin carboxyl-terminal hydrolase isozyme L1 (UCHL1), P4HA1,
actin-related protein 2 (ACTR2), protein S100A13, mitochondrial
oligoribonuclease (REXO2), and the chloride intracellular chan-
nel 4 (CLIC4) were measured in the tumor. These proteins were
more abundant in CAFs than cancer cells, suggesting that CAFs
contribute to a large extent to the proteome of hepatocellular
carcinomas.[122]
2.2. CAF Metabolism Unraveled by Total Proteome Analysis
MS-proteomics contributed to uncover metabolic rewiring as-
sociated with fibroblast activation. Notably, highly metabolically
active cancer cells release reactive oxygen species, which, in
turn, induce oxidative stress in the adjacent fibroblasts and ac-
tivate HIF1, through the stabilization of HIF1α subunit, and
NF-kB. HIF1 and NF-kB activation increases autophagy, which
mediates CAV1 degradation.[77,123–126] MS analysis provided first
hints that HIF1α and NF-kB activation, as well as CAV1 down-
regulation, are key drivers of the metabolic rewiring that oc-
curs in fibroblasts upon activation into CAFs. Overexpression of
HIF1α or the NF-kB-activator kinase IKBKE induced upregula-
tion of glycolytic enzymes in hTERT-BJ1 human immortalized
foreskin fibroblasts.[92] Similarly, CAV1-depleted murine embry-
onic fibroblasts and mesenchymal stem cells had increased lev-
els of glycolytic enzymes when compared with wild type cells,
and CAV1 silencing in these cells was sufficient to induce tumor
growth when fibroblasts were cotransplanted with MDA-MB-231
xenografts.[127] These studies led to formulate the “reverse War-
burg effect” theory in CAFs.[128] Proteomic analysis also provided
first hints that CAV1-silenced cells had enhanced oxidative stress
by increasing levels of proteins related to this process, thus sug-
gesting that CAV1 loss stabilized HIF1α through induction of re-
active oxygen species production in a feed-forward loop.[128–131]
Accordingly, overexpression of antioxidant superoxide dismutase
2 inCav1-deficient fibroblasts counteracted their protumorigenic
effect.[131] In follow up studies, it was found that CAFs activated
by oxidative stress increased secretion of lactate through upregu-
lation of the lactate exporter MCT4.[132–134] CAF-secreted lactate
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was then taken up by surrounding cancer cells and converted
into pyruvate, which fueled the tricarboxylic acid (TCA) cycle and
oxidative phosphorylation to support biosynthetic processes and
ATP production.[132,134]
The above pioneering studies led to investigate reciprocal
metabolic crosstalk between CAFs and cancer cells in other tu-
mor models. In in vitro setups and syngeneic/xenograft models
of subcutaneously/orthotopically cotransplanted pancreatic stel-
late cells (PSCs) and PDAC cells, cancer cells induced autophagy-
dependent secretion of alanine in PSCs. Alanine was taken up
by cancer cells and converted into pyruvate to selectively sup-
port mitochondrial metabolism for the biosynthesis of non-
essential amino acids and lipids without affecting glycolysis. This
metabolic crosstalk supported cancer cell proliferation under low
nutrient culture conditions.[135] High grade serous ovarian can-
cer cells (HeyA8 and SKOV3) secreted lactate, which was taken
up by patient-derived CAFs to fuel TCA cycle and support glu-
tamine synthesis, in nutrient-deprived conditions. CAF-secreted
glutamine was then used by cancer cells for nucleotide syn-
thesis through the TCA cycle. Targeting glutamine synthetase
in the stroma and glutaminase in the cancer cells blocked this
metabolic symbiosis and reduced tumor growth, burden, and
metastasis in a SKOV3 orthotopic tumor model.[136] EVs secreted
by patient-derived prostate CAFs and pancreatic CAF-19 line sup-
ported growth of pancreatic and prostate cancer cell lines via
KRas-independent mechanisms. CAF-derived EVs taken up by
cancer cells provided a wide range of metabolites and miRNAs,
which decreased oxygen consumption rate, while enhanced gly-
colysis and reductive glutaminemetabolism for fatty acid synthe-
sis in the cancer cells.[137]
2.3. CAF Functions Revealed by Secretome Analysis
To identify CAF-derived regulators of cancer cell proliferation,
the CM of paired CAFs and normal fibroblasts isolated from col-
orectal adenocarcinoma and adjacent normal tissue were com-
pared. Both cell types expressed α-SMA and vimentin and their
secretome had similar composition and anti-proliferative func-
tions. The proliferation of LoVo and HT-29 cancer cells in vitro
and the growth of LoVo xenografts in vivo decreased when can-
cer cells were cocultured or cotransplanted with CAFs or nor-
mal fibroblasts. The CM contained proteins related to ECM, ad-
hesion, motility, inflammation, and proliferation. Among those,
follistatin-related protein 1 (FSTL1) and transgelin (TAGLN) con-
trolled CAF antiproliferative function.[138] In human gastric can-
cer with lymph node metastasis, low levels of the ECM adap-
tor protein like TGF-β-induced gene-h3 were measured in the
CAF secretome. TGF-β-induced gene-h3 inhibits insulin-like
growth factor-2-stimulated cancer cell migration and prolifer-
ation, and growth of gastric cancer xenografts cotransplanted
with fibroblasts.[117] MS also unveiled the mechanisms under-
pinning the oncogenic effect of stromal Pten-loss (see above).
Pten-loss in CAFs induced miR-320 downregulation and this,
in turn, increased the secretion of lysyl oxidase homolog 2
(LOXL2), bonemorphogenetic protein 1, thrombospondin 1,ma-
trix metalloproteinase-2, MMP9, and elastin microfibril inter-
face 2. The latter two promoted invasive behavior of DB7 can-
cer cells and ECs, respectively.[139] MS-secretomics and antibody
array analyses of CM identified CAF-derived regulators of colon
cancer progression. Proteins released by patient-derived CAFs
were compared with those secreted by mesenchymal precursor
cells (MSCs) derived from sternal bone marrow aspirates and
TGF-β-treated MSCs. Proteins secreted by CAFs encompassed
ECM components and modifiers, chemokines, growth fac-
tors, anti-inflammatory/antioxidant, chaperones, metabolic, and
cytoskeletal-related proteins. The secretion of MMP3, Cathep-
sin D, HGF, tissue inhibitors of metalloproteinase-1 (TIMP1),
secreted protein acidic and rich in cysteine (SPARC), hyaluro-
nan and proteoglycan link protein 1 (HAPLN1), GAL1, CXCL12,
ED-A, and TNC was confirmed in vitro using western blot and
ELISA. A positive staining for the latter three was shown in
the α-SMA+ stroma of colon cancer patient samples.[140] The
comparison of CM from patient-derived oral SCC CAFs with
that of fibroblasts isolated from healthy oral mucosa showed
that CAFs secrete more proteins related to collagen metabolism,
ECM organization, and disassembly. RT-qPCR and ELISA anal-
yses confirmed increased levels of fibronectin type III domain-
containing 1 (FNDC1), serpin peptidase inhibitor type 1 (SER-
PINE1), and stanniocalcin 2 (STC2) in CAFs compared with nor-
mal fibroblasts across different CAF cell lines, and in normal
fibroblasts upon TGF-β-stimulation.[141] Our group has discov-
ered that upon activation, CAFs secrete high levels of CLIC3,
a protein that was previously known to be intracellular. CLIC3
was found to be a glutathione-dependent oxidoreductase abun-
dantly expressed inmammary and ovarian CAFs, as well as in the
stroma of highly invasive breast and ovarian cancers. Extracellu-
lar CLIC3 enhanced vascularization of matrigel plugs subcuta-
neously implanted and invasion in MCF10DCIS.com xenografts
through the activation of TGM2.[120] In α-SMA+ and FAP+ CT5.3
patient-derived colon cancer CAFs, FAP expression decreased
levels of the anti-angiogenic pigment epithelium-derived factor
(PEDF) while increased ANG1 and VEGFC to promote angiogen-
esis and lymphangiogenesis. Accordingly, FAP-silenced CAFs in-
hibited while FAP-overexpressing CAFs promoted EC sprouting
in vitro.[142] Similarly, pharmacological inhibition of FAP activ-
ity in the syngeneic tumor model of CT26 colon cancer reduced
tumor vascularization. Moreover, genetic deletion of FAP prior
to tumor onset in KRasG12D-driven model of lung adenocarci-
noma and in CT26 tumors, as well as pharmacological inhibi-
tion of FAP, reduced cancer cell proliferation via activation of
ECM/integrin-mediated signaling.[143] FAP also controlled the se-
cretion of ADAMTS8 and MMP1, the cancer-specific cleavage
of collagens and other secreted proteins.[142] To determine how
CAFs contribute to the proteolysis of the tumor ECM, the CM
of patient-derived gastric CAFs was compared to that of adjacent
tissue-derived fibroblasts. Gastric CAFs upregulated the secre-
tion of different MMPs. Using MS to identify fragments gen-
erated by proteolytic cleavage, MMP1 and MMP3 were found
highly active in the secretome of CAFs. Enhanced levels and ac-
tivity of MMPs were confirmed by western blot, enzymatic activ-
ity assays, and imaging techniques in CAFs cotransplanted with
MKN45 gastric cancer cell xenografts. Functional assays with
neutralizing antibodies and specific inhibitors for these proteases
further demonstrated the pro-migratory capacity of CAF-derived
MMPs on cancer cells.[144] Dermal fibroblasts isolated from Timp-
deficient mice had a myofibroblast-like phenotype and produced
EVs with a different content compared with wild-type fibroblasts.
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EVs from Timp-deficient fibroblasts were enriched for ECM pro-
teins, including LOXL2, TNC, and ADAM10. ADAM10-rich EVs
promoted motility of MDA-MB-231 cancer cells, and growth and
metastasis of MDA-MB-231 xenografts. Similarly, ADAM10-rich
EVs from patient-derived head and neck SCC CAFs promoted
MDA-MB-231migration.[145] Overall, these studies highlight that
the secretome is diverse in different CAFs; this may be a further
indication of the heterogeneity and plasticity of these cells.
Also, the ECM derived from cells and tissues has been an-
alyzed by MS (reviewed in Ref. 146); however, so far, only
few studies have measured the ECM specifically secreted by
fibroblasts[120,147] On the contrary, several works have analyzed
the composition of the ECM in tumor tissues.[42,148,149] Recently,
such analysis has been performed also on ECM generated by
an innovative approach of in situ decellularization of tissues
(ISDot).[150] Because in tissues the ECM can be produced by
cancer and stromal cells, to address the cell-specific contribu-
tion, human cancer cells can be transplanted into mice. This
approach led to proof that, in melanoma xenografts, the tumor
ECMwas produced by both human cancer cells andmurine stro-
mal cells.[151] From these studies, Naba and co-workers have de-
fined an accurate list of ECM proteins and proteins that can
interact with the ECM or remodel it, which they have called
“matrisome”.[151]
2.4. CAF Consensus Proteome and Secretome
The lack of molecular markers unique for CAFs hindered the
study of these cells. A key example is the challenge of isolat-
ing CAFs from tissues. The most used strategies are based on
the isolation of cells expressing few known CAF markers, such
as PDGFR or FAP, or by excluding cells expressing CD45, Ep-
CAM, or Pecam1. However, CAFs are heterogeneous and using
a single marker for their isolation may lead to the selection of a
subpopulation only; negative selection allows isolation of hetero-
geneous CAFs, but could leave unwanted cells with the fibrob-
lasts. Available proteomic data could be exploited to identify sub-
sets of proteins consistently expressed by these cells that could
help to establish panel of markers for their isolation and char-
acterization. Moreover, since CAFs are highly secretory cells, a
better characterization of their secretome could provide hints for
prognostic and diagnostic markers. Identifying molecular mark-
ers specific for CAF subpopulations could also help to define
their specialized secretory phenotype. Here we report an initial
draft of the CAF consensus proteome (Figure 3) and secretome
(Figure 4) based on the most in depth proteomic studies that
we have found in the literature. For the consensus proteome we
identified four studies which compared CAFs with their normal
fibroblast counterpart (Table 1).[116,117,120,121] From each of those
we considered the proteins differentially regulated between nor-
mal fibroblasts and CAFs as statistically assessed by the authors
(only exception is Ref. 121: the original study reported only up-
regulated proteins, and here we report up and downregulated
proteins based on a commonly used minimum fold change of
two). Proteins regulated in at least half of the studies were used
to build up a physical and functional interaction network with
STRING[152] (Figure 3). For the consensus secretome, we se-
lected the proteins commonly identified in at least three out of
the five studies (Table 2).[120,138,140,141,144] To increase the confi-
dence that those proteins are secreted, only the ones with a sig-
nal peptide (based on Uniprot[153]) and/or included in the hu-
man “matrisome”[154] were included in the STRING network[152]
(Figure 4). This analysis highlighted several highly connected
clusters, which were visualized with Cytoscape[155] and anno-
tated according to the function (literature-based) of the proteins
(Figures 3 and 4).
3. Future Perspectives
CAFs have emerged as key players in the development of cancer
pathology, but how these manipulators of the tumor microenvi-
ronment influence tumors is still largely unknown and rather
controversial. Modern MS technology has the potential to pro-
vide valuable insights to answer this question, particularly to shed
light on the reciprocal crosstalk between CAFs and other cell
types in tumors and their heterogeneity.
Over the past decade, MS-proteomics has broadened its ap-
plications for biology.[156,157] This has been achieved with the ad-
vances in MS technology which allow measuring proteomes and
posttranslational modifications (PTMs) with high accuracy and
to exceptional depth. Mass analyzers can now achieve unprece-
dented high resolution, such as the high field Orbitrap.[158] Im-
proved sample preparation prior to MS analysis also contributed
to increase the coverage of the proteomes. Currently, high pH RP
chromatography is a preferred method for peptide fractionation
because it is orthogonal to the RP chromatography that is usually
coupled on line to the mass spectrometer. This approach allows
exceptional peptide separation resolution.[159] Thanks to these
improvements great depth can be achieved starting from sub-
milligram amounts of sample,[160,161] thus making MS a unique
tool to assess complex biological systems that better mimic the
in vivo situation, such as primary cells, heterotypic cultures,
and cells cultured in 3D matrices. Also the robustness of pro-
tein quantification has improved. Software that use advanced
algorithms[162,163] can accurately quantify peptides and PTMs us-
ing different quantification approaches, including stable isotope
labeling with amino acids in cell culture (SILAC),[164] tandem
mass tag,[165] and label free.
To unravel the crosstalk between CAFs and other cell types
using heterotypic cultures, modern MS-proteomics can be com-
bined with cell-type specific labeling with amino acid precursors
(CTAP).[166,167] With this technique, cell type specific labeling is
achieved through the cell specific expression of non-mammalian
enzymes that convert specific precursors into the essential amino
acid l-lysine. With CTAP cells are cultured for up to 7 days in the
presence of heavy and light precursors. CTAP has recently un-
raveled the oncogenic KRasG12D-induced reciprocal signaling that
supports cancer cell proliferation and apoptosis in heterotypic
co-culture of PSCs and PDAC cells.[168] Also SILAC can be used
to assess reciprocal signaling in co-cultured cells. In this case,
cells labeled with heavy or light amino acids are co-cultured in
the absence of amino acids. For this reason, co-cultures can last
only for a short time, hours, to investigate dynamic signaling
based on PTMs. SILAC also offers opportunities to investigate
the transfer of proteins between CAFs and other cells. In co-
cultures, CAFs transfer proteins, lipids, and RNAs to cancer cells
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Figure 3. Consensus proteome. Proteins that were found consistently up- (red) and downregulated (blue) in the MS-proteomic comparisons listed in
Table 1 between matched CAFs and normal fibroblasts. Protein–protein interactions were define with STRING (version 10.5; all interaction sources were
enabled and minimum interaction score of 0.4 was required) and visualized with Cytoscape.
Table 1. Datasets used for the CAF proteome consensus signature in Figure 3.
Tissue of origin (specie) Quantification method Number of proteins
identified
Reference
Sporadic colon cancer (mouse) Fourplex iTRAQ 1353 [116]
Gastric cancer (human) Fourplex iTRAQ 768 [117]
Breast cancer (human) SILAC 4113 [120]
Breast cancer (human) Label-free quantification 4094 [121]
to influence their behavior.[114,115,169] With Trans-SILAC,[170] it is
possible to measure the repertoire of transferred proteins from
SILAC-labeled CAFs to other unlabeled cells in co-cultures.
There are increasing evidences that CAF phenotypes are un-
derpinned by epigenetic modifications,[171] such as histone/DNA
methylation and acetylation. Also CAF metabolism can con-
trol their activation.[172] Epigenetics and metabolism can be
tightly intertwined because Acetyl-CoA and methionine provide
building blocks for histone/DNA PTMs. MS-proteomics has
been recently used to trace the fate of stable isotope labeled
metabolites into PTMs, thus offering a unique opportunity to ex-
plore the relationship between fibroblast metabolism, epigenet-
ics, and phenotype.[173]
The mass cytometry by TOF (CyTOF) platform combines in-
dividual cell separation by flow cytometry with elemental metal
isotope-conjugated antibody (up to 40 antibody can be labeled
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Figure 4. Consensus secretome. Secreted proteins that were consistently identified in the MS-proteomic analysis of CAF-derived conditioned media
listed in Table 2. Protein–protein interactions were define with STRING (version 10.5; the active interaction sources were “experiments”, “databases”,
and “co-expression”, and minimum interaction score of 0.7 was required) and visualized with Cytoscape.
Table 2. Datasets used for the CAF secretome consensus signature in Figure 4.
CAF tissue of origin (specie) Secretome enrichment strategy Number of proteins
identified
Reference
Colon cancer (human) Ultrafiltration with Amicon Centriprep tubes YM-3 367 [140]
Gastric cancer (human) Ultrafiltration with Amicon Ultra 3 kDa 1460 [144]
Colon cancer (human) Ultrafiltration with Amicon Ultra 3 kDa 227 [138]
Oral squamous cell carcinoma (human) Ultrafiltration with Amicon Ultra 3 kDa 271 [141]
Mammary tumor (human) Affinity based (Strataclean resin) 1527 [120]
in a single experiment). These labeled antibodies are used to
label cells and can be detected by TOF mass analyzer.[174,175]
CyTOF has been used to map cell subset–specific phenotypes
of immune cells in clear cell renal carcinoma[176] and early lung
adenocarcinoma.[33] A similar approach could help resolving the
heterogeneity of CAF subpopulations in tumor tissues by using
antibodies that detect knownCAFmarkers, such as α-SMA, FAP,
FSP1/S100A4, and PDGFRs, or proteins found repeatedly in-
duced in CAFs, such as those reported in Figure 3, andmolecules
that dictate their functions, such as IL-6, CXCL12, and CLIC3.
Once CAF subpopulations are identified, and strategies to iso-
late them from tumor tissues set up, in-depth molecular and
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Figure 5. MS-proteomics and CAFs. Scheme showing how MS-
proteomics can contribute to understand CAF biology. TME, tumor
microenvironment.
functional characterization can be performed. MS could also
visualize the spatial distribution of CAF subpopulations within
the stroma in intact tissue samples. MALDI coupled with TOF
instruments[177] has been the most utilized MS imaging tech-
nique to visualize proteins; tissues are embedded into a ma-
trix and this allows efficient ionization of peptides and pro-
teins (intact, top-down, or digested, bottom-up) for MS analy-
sis. More recently nanospray desorption ESI[178] coupled with
high-resolution mass analyzers has been used to identify pep-
tides based on top-down MS analysis.[179] Both approaches can
reachmicrometer spatial resolution; however, nanospray desorp-
tion ESI has the advantage in that it requires minimal sample
preparation before MS acquisition while MALDI achieves better
ionization efficiency of protein and peptides.
In conclusion, the technological advances achieved over
the past decade are opening exciting avenues to a deeper
understanding of the biology of CAFs and contribute to
provide insights to therapeutically target the stromal com-
partment to interfere with cancer progression and invasion
(Figure 5).
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